Skip to main content
. Author manuscript; available in PMC: 2013 Aug 2.
Published in final edited form as: Immunol Invest. 2012;41(0):680–710. doi: 10.3109/08820139.2012.703745

Figure 5.

Figure 5

RCC patients developed much reduced peripheral blood MDSCs and normalized T cell responses during 2 months of sunitinib treatment. Red blocks display average % frequency of MDSCs in peripheral blood of Normal Donors vs RCC patients before and during sunitinib treatment. Vertical bars display % of CD3+ T cells producing IFN-γ which normalized during sunitinib treatment.